JM

Management's Discussion & Analysis — Q1 2026

Filed Apr 30, 2026 · 44 pages · MD&A

Open original

Document

Revenue of $4.1M was driven by a single Merevix milestone recognized during the quarter.

Phase II topline data for CSB-204 is now expected in H2 2026; commercial launch timing is unchanged from prior guidance.

Flags raised

Warning74
Revenue restated in the financials but not flagged in the narrative
Contradiction

Metadata

SEDAR+ ID
SP-2026-04-30-CSBX-MDA-12290
Issuer
Cascade BioSciences Inc.
Type
MD&A
Filed
Apr 30, 2026
Period end
Mar 31, 2026
Pages
44